Prognosis
J&J to Resume EU Vaccine Shipments After Review of Clot Risk
- EU regulator says benefits of the shot outweigh risks
- EMA assessment echoes its statements on AstraZeneca shot
This article is for subscribers only.
Johnson & Johnson will restart deliveries of its Covid-19 vaccine to the European Union after the bloc’s drug regulator said the benefits of the shot outweigh the risks of a possible link with cases of rare blood clots.
The European Medicines Agency assessment on Tuesday echoed its review of the vaccine from AstraZeneca Plc, which has also been linked with the rare clot. In both cases, the regulator noted that Covid can be fatal and the use of vaccines is crucial to fighting the virus.